Webinars and Sponsored Roundtables — Register Now

Wednesday, July 29, 2026, 1:00-2:00 PM ET
Learn about digital pathology technology that is future-ready, yet practical for today’s
laboratory needs.

Webinar presenters Scott Hammond, Senior Systems Consultant, Digital Pathology Division, Wexner Medical Center, Department of Pathology, and Ursula Hofer, Imaging Technologist, Pathology Digital Imaging Lab, Wexner Medical Center, Department of Pathology, and Sandra Banky, PA(ASCP), Director of Operations, Wexner Medical Center, Department of Pathology.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

December 2025

Anatomic pathology selected abstracts

December 2025—Unusual morphologic patterns of breast carcinoma can raise diagnostic consideration for metastasis or special breast cancer subtypes and, thereby, impact clinical management and treatment. The authors conducted a study in which they described rare invasive breast cancers that mimic serous carcinoma of the gynecologic tract (serous-like breast carcinomas, SLBC) and characterized their clinicopathologic, immunophenotypic, and genetic features. The patients evaluated in the study were female (n = 15; median age, 49 years) and did not have a history of gynecologic malignancy. SLBC were characterized histologically by angulated, branched, sometimes anastomosing glands with micropapillary or pseudopapillary luminal projections in desmoplastic stroma. Most SLBC were triple negative (n = 10) or HER2 positive (n = 2) and grade 2 or 3, while some were estrogen receptor low positive/HER2 negative and low grade (n = 3). CK5/6 was positive irrespective of grade or receptor status (10 of 10).

Molecular pathology selected abstracts

December 2025—Two studies explore the evolution of Mycobacterium tuberculosis and the significance of GATA1 mutations in children with Down syndrome. The first study reveals diversity in virulence gene expression across Mtb clinical isolates, with variants in the regulator whiB6 linked to decreased expression of virulence factors and increased transmission of drug-resistant strains. The second study investigates the clinical significance of GATA1 mutations in neonates with Down syndrome, finding that the presence of GATA1s mutations at birth is a strong predictor of myeloid leukemia associated with Down syndrome (ML-DS).

Newsbytes

December 2025—Mayo Clinic recently introduced Mayo Clinic Platform_Insights, an offering designed to advance the adoption of artificial intelligence by giving health care organizations around the world access to Mayo Clinic’s digital expertise, data-driven insights, and clinical knowledge. “When organizations partner with us, they gain access to proven clinical and administrative solutions and the technical framework to integrate them seamlessly,” according to a press statement from Maneesh Goyal, chief operating officer for Mayo Clinic Platform, an initiative that brings together health systems, innovators, and researchers to support responsible AI development worldwide.

Q&A column

December 2025
Q. Now that the CMS allows direct observation for competency assessment to be performed virtually, does the CAP also allow it? If so, can you provide guidance? Read answer.

Q. We have implemented quality control at 10x in accordance with the Westgard rules. I use three levels of QC. If the results of two levels of QC are moving properly above and below the mean and only one level is showing a trend of a 10x rule violation, what corrective action should I take? Read answer.

Put It on the Board

December 2025—A new Clinical and Laboratory Standards Institute document on external laboratory transport is expected to be released early next year. “It’s the first comprehensive framework for evaluating external specimen transport systems,” says Joe Wiencek, PhD, D(ABCC), document development chair and medical director and associate professor of pathology, microbiology, and immunology at Vanderbilt University Medical Center.